Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an early phase research study looking at whether an experimental gene transfer, LVsh5/C46 (also known as Cal-1), is safe and if it can protect the immune system from the effects of HIV without the use of antiretroviral drugs.
Cal-1 is an experimental gene transfer agent designed to inhibit HIV infection through 2 active parts:
It is estimated that 33 million individuals are currently infected with HIV. HIV/AIDS is a disease that impairs immune function, primarily by decreasing CD4+ T lymphocytes. The progression can be contained by daily dosing with antiretroviral therapy (ART) but there are side effects that can be treatment limiting, and the development of HIV drug resistance can force the physician to modify the ART regimen. There are no effective vaccines currently available for HIV.
LVsh5/C46 (also known as Cal-1) is a dual therapeutic, self-inactivating lentiviral vector that encodes for both a short hairpin RNA against the HIV-1 co-receptor CCR5 (sh5) and a HIV-1 fusion inhibitor, C46 and inhibits two processes required for HIV-1 infection:
The rationale is that Cal-1 introduced into hematopoietic progenitor/stem cells (HSPC) and mature CD4+ T lymphocytes will protect these cells and their progeny cells from HIV-1 infection and its pathogenic sequelae. This may provide a continuous means of controlling HIV-1 after a single or infrequent dose(s), thereby decreasing or delaying (partially or completely) the need for antiretroviral drug therapy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| No busulfan pre-conditioning | Experimental | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes without busulfan preconditioning |
|
| 1 x 4mg/kg busulfan preconditioning | Experimental | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with single 4mg/kg busulfan dose administered as pre-conditioning for transplant |
|
| 2 x 4mg/kg busulfan pre-conditioning | Experimental | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with two 4mg/kg busulfan doses administered as pre-conditioning for transplant |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Busulfan | Drug | Intravenous busulfan |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Severe and Life-threatening Adverse Events (AEs) | Up to 48 weeks | |
| Number of Participants With Severe or Life-threatening AEs Related to CSL202 | Up to 48 weeks | |
| Number of Participants With the Presence of Replication-competent Retrovirus | Up to 48 weeks | |
| Number of Participants With Predominant Integration Site Analysis | Vector Integration Site Analysis performed only when Cal-1 Marking is >= 1%. | Up to 48 weeks |
| Mean Cell Dose for CD4+ Cells (Ttn) | Up to 48 weeks | |
| Mean Cell Dose for CD34+ Cells (HSPCtn) | Up to 48 weeks | |
| Percent Transduction Efficiency of CD4+ Cells (Ttn) and CD34+ Cells (HSPCtn) of Final Cell Product | Up to 48 weeks | |
| Total Area Under the Curve (AUC) for Busulfan | Cohort 3: Total AUC = first dose AUC value + second dose AUC value | Up to 48 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Cal-1 Marking in Peripheral Blood | Up to 48 weeks | |
| Cal-1 Marking in Gut-associated Lymphoid Tissue (GALT) (10-15 cm) | Samples were collected via endoscopic biopsy from the sigmoid colon: 10-15 cm from the anal margin |
Not provided
Inclusion Criteria:
Prior to any study-related procedures, signed informed consent indicating that they understand the purpose, risks and procedures required for the study and are willing to participate in the study
Individuals aged 18 to 65 years of age (inclusive) at time of consent
Documented HIV-1 infection ≥ 6 months prior to Screening 1
Previous treatment with antiretroviral agents that had a demonstrated suppressive effect (defined as plasma HIV RNA ≤ 50 copies/ml)
A documented viable ART regimen option, as determined by the Investigator, taking into account prior ART experience and HIV geno/phenotyping analyses
Not taking antiretroviral therapy for ≥ 6 weeks prior to Screening 1, for one or more of the following reasons:
i) Concerns over short-term or long-term toxicities associated with antiretroviral agents, or ii) Treatment fatigue from the daily regimen of life-long therapy
Plasma HIV-1 viral RNA ≥ 5,000 copies/mL and ≤ 100,000 copies/ml at Screening 1 and Screening 2
CD4+ T lymphocyte count ≥ 500 cells/µl at Screening 1 and Screening 2
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ronald Mitsuyasu, M.D. | University of California, Los Angeles | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCLA CARE Center | Los Angeles | California | 90035 | United States | ||
| Quest Clinical Research |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cohort 1 (CSL202 With No Busulfan) | Cal-1 modified Hematopoietic stem/progenitor cells (HSPC) and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning |
| FG001 | Cohort 2 (CSL202 With 1 Busulfan Dose) | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant Busulfan: Intravenous busulfan |
| FG002 | Cohort 3 (CSL202 With 2 Busulfan Doses) | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC) administered as pre-conditioning for transplant Busulfan: Intravenous busulfan |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cohort 1 (CSL202 With No Busulfan) | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning |
| BG001 | Cohort 2 (CSL202 With 1 Busulfan Dose) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Severe and Life-threatening Adverse Events (AEs) | Safety Population (SP): The safety population includes all enrolled subjects signing informed consent who started the interventional phase of the trial (i.e. CD4+ Apheresis and discontinued subjects who re-commenced ART) | Posted | Count of Participants | Participants | Up to 48 weeks |
|
Up to 48 weeks per participant
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cohort 1 (CSL202 With No Busulfan) | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202) without busulfan preconditioning |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| gastroenteritis | Gastrointestinal disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Neutropenia | Blood and lymphatic system disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Trial Registration Coordinator | CSL Behring | 484-878-4000 | clinicaltrials@cslbehring.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 8, 2015 | Jun 24, 2020 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Dec 15, 2017 | Jun 24, 2020 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D002066 | Busulfan |
| ID | Term |
|---|---|
| D002072 | Butylene Glycols |
| D006018 | Glycols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Cal-1 modified HSPC | Biological | Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1) |
|
|
| Cal-1 modified CD4+ T lymphocytes | Biological | CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1) |
|
|
| Up to 48 weeks |
| Cal-1 Marking in GALT (25-35 cm) | Samples were collected via endoscopic biopsy from the sigmoid colon: 25-35 cm from the anal margin | Up to 48 weeks |
| Cal-1 Marking in Bone Marrow | Up to 48 weeks |
| Cal-1 C46 Expression in Peripheral Blood | C46 relative expression will be analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and normalized to the expression of β2-microglobulin (β2M) mRNA | Up to 48 weeks |
| Cal-1 sh5 Expression in Peripheral Blood | sh5 relative expression will be analyzed by RT-qPCR and normalized to the expression of RNU38B microRNA | Up to 48 weeks |
| HIV Viral Load at Baseline Screening and Week 48 or at Anti-retroviral Therapy (ART) Re-commencement | Up to 48 weeks |
| CD4+ Count at Baseline Screening and Week 48 or at ART Re-commencement | Up to 48 weeks |
| Number of Participants With HIV-1 Tropism Shift | Shift from R5 to X4 or dual/mixed tropism | Up to 48 weeks |
| San Francisco |
| California |
| 94115 |
| United States |
Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant
Busulfan: Intravenous busulfan
| BG002 | Cohort 3 (CSL202 With 2 Busulfan Doses) | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC)administered as pre-conditioning for transplant Busulfan: Intravenous busulfan |
| BG003 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG002 | Cohort 3 (CSL202 With 2 Busulfan Doses) | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC) administered as pre-conditioning for transplant Busulfan: Intravenous busulfan |
|
|
| Primary | Number of Participants With Severe or Life-threatening AEs Related to CSL202 | SP | Posted | Count of Participants | Participants | Up to 48 weeks |
|
|
|
| Primary | Number of Participants With the Presence of Replication-competent Retrovirus | SP | Posted | Count of Participants | Participants | Up to 48 weeks |
|
|
|
| Primary | Number of Participants With Predominant Integration Site Analysis | Vector Integration Site Analysis performed only when Cal-1 Marking is >= 1%. | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Count of Participants | Participants | Up to 48 weeks |
|
|
|
| Primary | Mean Cell Dose for CD4+ Cells (Ttn) | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | Number (10^8 cells) | Up to 48 weeks |
|
|
|
| Primary | Mean Cell Dose for CD34+ Cells (HSPCtn) | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | Number (10^6 cells/kg body weight) | Up to 48 weeks |
|
|
|
| Primary | Percent Transduction Efficiency of CD4+ Cells (Ttn) and CD34+ Cells (HSPCtn) of Final Cell Product | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | Percent transduction efficiency | Up to 48 weeks |
|
|
|
| Primary | Total Area Under the Curve (AUC) for Busulfan | Cohort 3: Total AUC = first dose AUC value + second dose AUC value | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | micromolar*min | Up to 48 weeks |
|
|
|
| Secondary | Percent Cal-1 Marking in Peripheral Blood | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | percent Cal-1 marking | Up to 48 weeks |
|
|
|
| Secondary | Cal-1 Marking in Gut-associated Lymphoid Tissue (GALT) (10-15 cm) | Samples were collected via endoscopic biopsy from the sigmoid colon: 10-15 cm from the anal margin | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | copies/cell | Up to 48 weeks |
|
|
|
| Secondary | Cal-1 Marking in GALT (25-35 cm) | Samples were collected via endoscopic biopsy from the sigmoid colon: 25-35 cm from the anal margin | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | copies/cell | Up to 48 weeks |
|
|
|
| Secondary | Cal-1 Marking in Bone Marrow | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | copies/cell | Up to 48 weeks |
|
|
|
| Secondary | Cal-1 C46 Expression in Peripheral Blood | C46 relative expression will be analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) and normalized to the expression of β2-microglobulin (β2M) mRNA | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | units of relative expression | Up to 48 weeks |
|
|
|
| Secondary | Cal-1 sh5 Expression in Peripheral Blood | sh5 relative expression will be analyzed by RT-qPCR and normalized to the expression of RNU38B microRNA | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | units of relative expression | Up to 48 weeks |
|
|
|
| Secondary | HIV Viral Load at Baseline Screening and Week 48 or at Anti-retroviral Therapy (ART) Re-commencement | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | Log10 (copies/mL) | Up to 48 weeks |
|
|
|
| Secondary | CD4+ Count at Baseline Screening and Week 48 or at ART Re-commencement | SP (1 participant in Cohort 3 withdrew consent and did not receive busulfan or Ttn and HSPCtn) | Posted | Mean | Full Range | CD4+ cells/cubic mm | Up to 48 weeks |
|
|
|
| Secondary | Number of Participants With HIV-1 Tropism Shift | Shift from R5 to X4 or dual/mixed tropism | SP | Posted | Count of Participants | Participants | Up to 48 weeks |
|
|
|
| 0 |
| 4 |
| 0 |
| 4 |
| 4 |
| 4 |
| EG001 | Cohort 2 (CSL202 With 1 Busulfan Dose) | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), with single 4mg/kg busulfan dose administered as pre-conditioning for transplant Busulfan: Intravenous busulfan | 0 | 4 | 0 | 4 | 4 | 4 |
| EG002 | Cohort 3 (CSL202 With 2 Busulfan Doses) | Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes (CSL202), first busulfan dose = 3mg/kg and second busulfan dose adjusted (total target exposure of 8,000 μmolar/min AUC) administered as pre-conditioning for transplant Busulfan: Intravenous busulfan | 0 | 5 | 1 | 5 | 5 | 5 |
| Thrombocytopenia | Blood and lymphatic system disorders | Systematic Assessment |
|
| Leukopenia | Blood and lymphatic system disorders | Systematic Assessment |
|
| Fatigue | General disorders | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | Systematic Assessment |
|
| Chills | General disorders | Systematic Assessment |
|
| Skin odour abnormal | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Pain | General disorders | Systematic Assessment |
|
| Pyrexia | General disorders | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Alopecia | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Insomnia | Nervous system disorders | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Retching | Gastrointestinal disorders | Systematic Assessment |
|
| Toothache | Gastrointestinal disorders | Systematic Assessment |
|
| Asthenia | General disorders | Systematic Assessment |
|
| Malaise | General disorders | Systematic Assessment |
|
| Night Sweats | General disorders | Systematic Assessment |
|
| Cellulitis | Infections and infestations | Systematic Assessment |
|
| Sinusitis | Infections and infestations | Systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | Systematic Assessment |
|
| Dizziness | Nervous system disorders | Systematic Assessment |
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Acarodermatitis | Infections and infestations | Systematic Assessment |
|
| Haematospermia | Reproductive system and breast disorders | Systematic Assessment |
|
| Dermatitis allergic | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Rash vesicular | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Leukocytosis | Blood and lymphatic system disorders | Systematic Assessment |
|
| ear congestion | Ear and labyrinth disorders | Systematic Assessment |
|
| Eye irritation | Eye disorders | Systematic Assessment |
|
| Eye pruritus | Eye disorders | Systematic Assessment |
|
| Vision blurred | Eye disorders | Systematic Assessment |
|
| Abdominal distension | Gastrointestinal disorders | Systematic Assessment |
|
| Dry mouth | Gastrointestinal disorders | Systematic Assessment |
|
| Faeces soft | Gastrointestinal disorders | Systematic Assessment |
|
| Food poisoning | Gastrointestinal disorders | Systematic Assessment |
|
| Haematochezia | Gastrointestinal disorders | Systematic Assessment |
|
| Stomatitis | Gastrointestinal disorders | Systematic Assessment |
|
| Tongue discolouration | Gastrointestinal disorders | Systematic Assessment |
|
| Catheter site pain | General disorders | Systematic Assessment |
|
| Influenza like illness | General disorders | Systematic Assessment |
|
| Bronchitis | Infections and infestations | Systematic Assessment |
|
| Diverticulitis | Infections and infestations | Systematic Assessment |
|
| Gastroenteritis | Gastrointestinal disorders | Systematic Assessment |
|
| Gingivitis | Infections and infestations | Systematic Assessment |
|
| Secondary syphilis | Infections and infestations | Systematic Assessment |
|
| Staphylococcal infection | Infections and infestations | Systematic Assessment |
|
| Tinea pedis | Infections and infestations | Systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Head injury | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Road traffic accident | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Alanine aminotransferase increased | Investigations | Systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | Systematic Assessment |
|
| CD4 lymphocytes decreased | Investigations | Systematic Assessment |
|
| Bone pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Confusional state | Nervous system disorders | Systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | Systematic Assessment |
|
| Migraine | Nervous system disorders | Systematic Assessment |
|
| Paraesthesia | Nervous system disorders | Systematic Assessment |
|
| Somnolence | Nervous system disorders | Systematic Assessment |
|
| Depression | Psychiatric disorders | Systematic Assessment |
|
| Irritability | Psychiatric disorders | Systematic Assessment |
|
| Somnambulism | Psychiatric disorders | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Paranasal sinus hypersecretion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Sinus congestion | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Sneezing | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Throat irritation | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Tonsillar disorder | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Upper-airway cough syndrome | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Acne | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Dry skin | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Eosinophilic pustular folliculitis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Excoriation | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Photosensitivity reaction | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Rash pruritic | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Seborrhoeic dermatitis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Skin erosion | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Skin mass | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Urticaria | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Hot flush | Vascular disorders | Systematic Assessment |
|
Not provided
Not provided
| D015229 |
| Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D008698 |
| Mesylates |
| D000476 | Alkanesulfonates |
| D017738 | Alkanesulfonic Acids |
| D000473 | Alkanes |
| D006839 | Hydrocarbons, Acyclic |
| D006838 | Hydrocarbons |
| D013451 | Sulfonic Acids |
| D013456 | Sulfur Acids |
| D013457 | Sulfur Compounds |
|
|
|
|
|
|
|
|
|